Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="TEJPAR, S" or (type any "bookEditor journalEditor issueEditor" and editor="TEJPAR, S")

Add to list
The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP)

Kathleen Claes (UGent) , Karin Dahan, S Tejpar, Anne De Paepe (UGent) , Maryse Bonduelle, Marc Abramowicz, Christine Verellen, Denis Franchimont, Eric Van Cutsem and Alex Kartheuser

(2011) ACTA GASTRO-ENTEROLOGICA BELGICA. 74(3). p.421-426
Add to list
Familial adenomatous polyposis: clinical presentation, detection and surveillance

Stéphanie Laurent (UGent) , D Franchimont, JP Coppens, K Leunen, L Macken, Marc Peeters (UGent) , O Plomteux, M Polus, Bruce Poppe (UGent) , C Sempoux, et al.

(2011) ACTA GASTRO-ENTEROLOGICA BELGICA. 74(3). p.415-420
Add to list
Harmonization of molecular oncology testing in Belgium : introduction of KRAS testing for colorectal cancer

S Tejpar, P In't Veld, M Kockx, the Belgian Working group of Molecular Pathology, Claude Cuvelier (UGent) , Anne Hoorens (UGent) and Marleen Praet

(2009) BELGIAN JOURNAL OF MEDICAL ONCOLOGY. 3(1). p.16-22
Add to list
- Journal Article
- A1
Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer

A Debucquoy, K Haustermans, A Daemen, S Aydin, Louis Libbrecht (UGent) , O Gevaert, B De Moor, S Tejpar, WH McBride, F Penninckx, et al.

(2009) JOURNAL OF CLINICAL ONCOLOGY. 27(17). p.2751-2757
Add to list
- Conference Paper
- C1
Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease.

S TEJPAR, W DE ROOCK, B BIESMANS, J DE SCHUTTER, H PIESSEVAUX, Y HUMBLET, Marc Peeters (UGent) , I CELIK and E VAN CUTSEM

(2008) Gastrointestinal Cancers Symposium. p.411-411
Add to list
- Conference Paper
- C3
Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition.

B Jacobs, R Van Oirbeek, B Biesmans, S Fieuws, W De Roock, J De Schutter, Y Humblet, Marc Peeters (UGent) , E Van Cutsem and S Tejpar

(2008) EJC SUPPLEMENTS. 6(12). p.31-31
Add to list
- Conference Paper
- C3
DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease.

W De Roock, M Janssens, B Biesmans, B Jacobs, J De Schutter, Y Humblet, Marc Peeters (UGent) , E Van Cutsem, P Marynen and S Tejpar

(2008) EJC SUPPLEMENTS. 6(12). p.33-33
Add to list
- Conference Paper
- C1
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refactory metastatic colorectal cancer (mCRC), treated wth irinotecan (q2w) and escalating dose of cetuximab (q1w): the EVEREST experience (preliminary data)

S TEJPAR, Marc Peeters (UGent) , Y HUMBLET, J VERMORKEN, G DE HERTOGH, W DE ROOCK, J NIPPGEN, A VON HEYDEBROECK, C STROH and E VAN CUTSEM

(2008) Journal Clinical Oncology. 26. p.4001-4001
Add to list
- Conference Paper
- C1
The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab

S TEJPAR, Marc Peeters (UGent) , Y HUMBLET, H GELDERBLOM, J VERMORKEN, G DE HERTOGH, W DE ROOCK, J NIPPGEN, A VON HEYDERBRECK, C STROH, et al.

(2008) Annals of Oncology. 19(Suppl 6). p.019-019
Add to list
- Journal Article
- A1
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

W DE ROOCK, H PIESSEVAUX, J DE SCHUTTER, M JANSSENS, G DE HERTOGH, N PERSONENI, B BIESMANS, JL VAN LAETHEM, Marc Peeters (UGent) , Y HUMBLET, et al.

(2008) ANNALS OF ONCOLOGY. 19(3). p.508-515

Academic Bibliography

The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP)

Familial adenomatous polyposis: clinical presentation, detection and surveillance

Harmonization of molecular oncology testing in Belgium : introduction of KRAS testing for colorectal cancer

Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer

Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease.

Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition.

DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease.

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refactory metastatic colorectal cancer (mCRC), treated wth irinotecan (q2w) and escalating dose of cetuximab (q1w): the EVEREST experience (preliminary data)

The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Contents

Support

Contact